The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Empa) has emerged as a powerful cardioprotective agent, with benefits extending far beyond its original role in glycemic control for type 2 diabetes mellitus (T2DM). This evidence concerns the gene SLC5A2 and diabetes mellitus.